Comment on Proposed Rule Regarding Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds

Today, CSPI filed comments with the FDA urging the agency to assert a more active role in regulating health and safety with regard to consumer use of cannabis. Decriminalization and legalization of cannabis is occurring at the state level, producing a legal patchwork with inadequate policies and funding to protect consumers. Cannabinoids and the risks they may pose are poorly understood.

Yet cannabis-derived products, mostly containing cannabidiol (CBD), may be found today in hundreds of supplements, foods, and other products. This exploding marketplace for consumer goods is well out in front of federal law, which (despite its myriad flaws) historically provides the most robust assurance of safety and quality in food and drugs.